Vanderbilt researchers closer to building a brain in a dish

Human Brain Dissected / Source: MGN/Hikmet Gumus

NASHVILLE, Tenn. (WVLT) -- Researchers at Vanderbilt say they're one step closer to building a brain in a dish, CBS affiliate NewsChannel 5 reported.

Building a brain starts with studying cells.

"So one of the things we had to do was figure out the right environment to keep some of these cells alive," said Leon Bellan, Assistant Professor of Mechanical & Biomedical engineering at Vanderbilt University.

Bellan said cells can live in a special gel outside of the body.

"You can form what you call a hydro-gel. It's kind of like a gelatin dessert and turns out that cell love growing both on and in that," he said.

Creating 3D models of human organs such as the brain is a goal for Bellan and Ethan Lippmann, Assistant Professor of Chemical and Biomolecular Engineering. Having 3D model that mimics the body's vasculature would help in future drug testing and disease research, they said.

"When people think of neuro-degeneration they think about all Alzheimer's disease but really there's a lot of other facets of diseases that are encompassed in dementia," said Lippmann.

Lippmann said his uncle has Parkinson's disease, as do other family members.

"My uncle has Parkinson's disease, my father-in-law has Parkinson's disease, my great uncle who is now deceased had Parkinson's disease," he said.

He hopes this is the first step towards organoids, models of human organs. So far, NewsChannel 5 reported, they've created a blood-brain-barrier model that duplicates the endothelial barrier. Such barriers are critical since many things circulate in the blood that shouldn't get into your brain.

"Once we have the brain we would be more of a stage where we could test perspective drugs to see if we could correct diseases. We would be equipped to study how the brain and its vasculature degrade in the face of a disease. We would be in a situation where we would have a very robust model system that we could then use to probe all of these things that were very interested in and then hopefully help bring drugs to the clinic faster because that's really our ultimate goal," Lippmann said.